Prion Disease Treatment Market Report 2026

The prion disease treatment market size has grown strongly in recent years. It will grow from $3.02 billion in 2025 to $3.21 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rare disease research funding, neurological disorder awareness, expansion of genetic testing, academic clinical studies, specialty neurology centers growth.

The prion disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to novel molecule discovery programs, precision neurology approaches, biomarker based diagnostics, expanded orphan drug incentives, advanced neuro research collaborations. Major trends in the forecast period include targeted neurodegenerative drug research, advanced prion diagnostic testing, genetic risk screening programs, compassionate use therapy trials, integrated supportive care protocols.

The rising government investment in rare diseases is anticipated to drive the growth of the prion disease treatment market in the coming years. Rare diseases are medical conditions that affect a small portion of the population and are frequently chronic, progressive, and life-threatening. The increase in funding for rare diseases is due to enhanced government and philanthropic support, which is accelerating research projects, clinical trials, and the development of innovative therapies for conditions with significant unmet medical needs. Government investment in rare diseases fosters progress in prion disease treatment by supporting long-term foundational research, maintaining specialized laboratories and surveillance systems, promoting pharmaceutical innovation despite limited commercial incentives, and expediting the translation of discoveries into diagnostics and potential therapies. For example, in February 2024, according to the Department of Health and Social Care, a UK-based government body, a $17.3 million (£14 million) investment was allocated to establish the UK Rare Disease Research Platform, consisting of 11 research nodes nationwide and a central coordinating hub, aimed at encouraging coordinated collaboration among academic, clinical, and industry researchers, patients with rare diseases, research charities, and other stakeholders to accelerate advances in understanding, diagnosing, and treating rare diseases. Therefore, the rising government investment in rare diseases is propelling the growth of the prion disease treatment market.

Organizations operating in the prion disease treatment market are focusing on developing innovative methods such as viral vector-based gene therapy to deliver targeted treatments across the blood-brain barrier and slow disease progression. Viral vector-based gene therapy is a treatment that uses modified viruses to deliver therapeutic genes into specific cells, helping to correct or reduce disease-causing processes, such as misfolded prion proteins, by enabling targeted and long-lasting effects. For example, in February 2025, Apertura Gene Therapy, a US-based biotechnology company, supported the Broad Institute in developing a gene therapy for prion disease using an engineered AAV capsid targeting TfR1. The therapy delivers therapeutic genes across the blood-brain barrier, enabling widespread CNS distribution and potentially slowing or preventing prion protein accumulation. It offers high specificity, reduced off-target effects, and sustained therapeutic expression, representing a significant advancement over conventional treatments that primarily manage symptoms rather than modify disease progression. Overall, it represents a significant step forward in moving from symptomatic management toward disease-modifying interventions, potentially transforming the treatment landscape for prion disorders.

In June 2023, Sangamo Therapeutics Inc., a US-based genomic medicine company, formed a partnership with Voyager Therapeutics, Inc., entering into a definitive license agreement to develop a potential epigenetic regulation therapy for prion disease. Through this collaboration, Sangamo Therapeutics Inc. and Voyager Therapeutics Inc. aim to integrate Sangamo’s zinc finger transcriptional regulators with Voyager’s TRACER capsid technology capable of crossing the blood-brain barrier, targeting the creation of a novel treatment for the rapidly progressing and fatal neurodegenerative disorder. Voyager Therapeutics Inc. is a US-based biotechnology company focused on capsid discovery and gene therapy delivery platforms.

Major companies operating in the prion disease treatment market are Ionis Pharmaceuticals Inc., Broad Institute of MIT and Harvard, Sangamo Therapeutics Inc., Gate Bioscience, Apertura Gene Therapy, Sibylla Biotech, Case Western Reserve University, and National Prion Clinic.

Tariffs are influencing the prion disease treatment market by raising the cost of imported laboratory equipment, diagnostic kits, and specialized pharmaceutical inputs. Higher duties on research instruments and biotech materials are increasing operational expenses for research institutes and specialty care centers. Regions dependent on imported diagnostic technologies and niche drug compounds are facing higher treatment and trial costs. Advanced testing and research segments are more affected than basic supportive care services. Smaller research programs are especially sensitive to price increases. At the same time, tariffs are encouraging local production of diagnostic reagents and lab tools. This is gradually strengthening domestic biotech supply capabilities.

The prion disease treatment market research report is one of a series of new reports that provides prion disease treatment market statistics, including prion disease treatment industry global market size, regional shares, competitors with a prion disease treatment market share, detailed prion disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the prion disease treatment industry. This prion disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prion disease treatment refers to medical and supportive care strategies aimed at managing diseases caused by misfolded prion proteins, such as Creutzfeldt-Jakob disease, which result in progressive neurodegeneration and fatal brain damage. Current treatments focus on symptom management, supportive interventions, and slowing disease progression, as no definitive cure or disease-reversing therapy exists at present.

The key disease types of prion disease treatment include medication, supportive care, and other treatment options. Creutzfeldt-Jakob Disease is a rapidly progressing, fatal neurodegenerative disorder caused by abnormal prion proteins, resulting in brain damage and severe neurological symptoms. Treatments are administered via different routes, including oral and parenteral, and are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. These treatments serve various end users, including hospitals, specialty clinics, research institutes, and other relevant recipients.

The prion disease treatment market includes revenues earned by entities through clinical research, drug development, diagnostic services, patient monitoring, genetic testing, counseling services, home healthcare, hospital care, laboratory services, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.